Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Conditions:   Multiple Myeloma;   Multiple Myeloma in Relapse;   Neoplasm, Plasma Cell Intervention:   Biological: BCMA CAR-T cells Sponsor:   Chongqing Precision Biotech Co., Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials